<DOC>
	<DOCNO>NCT00552149</DOCNO>
	<brief_summary>A Multicenter , Randomized Phase II Trial Assessing Activity Gemcitabine - Oxaliplatin Chemotherapy Alone Combination Cetuximab Patients Advanced Biliary Cancer .</brief_summary>
	<brief_title>Biliary Cancers : EGFR INhibitor , Gemcitabine Oxaliplatin</brief_title>
	<detailed_description>The BINGO trial open-label randomize phase II study evaluate efficacy tolerance gemcitabine-oxaliplatin combination chemotherapy ( GEMOX regimen ) alone combination cetuximab patient ( pt ) ABC . The BINGO study also comprise ancillary translational research functional imaging study aim identify marker predictive treatment efficacy ABC . All eligible pt randomize 1:1 receive : - Arm A : GEMOX alone every two week . - Arm B : GEMOX + cetuximab every two week . Randomization stratify accord : 1. tumor stage ( locally advance vs metastatic ) , 2. primary tumor location ( gallbladder v non-gallbladder ) , 3. prior treatment ( surgery radiotherapy brachytherapy photodynamic therapy [ PDT ] adjuvant chemotherapy v none ) , 4. center . EGFR tumor status assess every pt immunohistochemistry ( IHC ) use biopsy surgical material , time prior inclusion study , neither inclusion/exclusion criterion stratification factor .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Adenocarcinoma biliary tract ( gallbladder , intra and/or extrahepatic bile duct , ampulla Vater ) : Cytologically histologically confirm . In case uncertain biliary tract origin ( e.g. , intrahepatic , peripheral cholangiocarcinomas ) , inclusion possible ) extensive search primary ( thoracic abdominopelvic CT scan , colonoscopy , upper digestive endoscopy , serum PSA level men mammography woman , FDGPET possible ) negative ; ii ) histological examination consistent bile duct adenocarcinoma ( IHC ideally perform consistent biliary primary , e.g. , positive cytokeratin 7 19 negative cytokeratin 20 ) . amenable curative resection , recurrent resection ( i.e. , locally advanced metastatic ) , With least one unidimensionally measurable target lesion nonirradiated , nonPDTtreated area ( long diameter 1 cm [ spiral CT scan ] ) , 2 cm [ conventional CT scan ] ) . With biliary obstruction control , 2 . Age 18 75 year . 3 . World Health Organization ( WHO ) performance status 0 1 . 4 . Life expectancy high 3 month . 5 . No prior chemotherapy advance disease . Previous adjuvant chemotherapy allow ( complete least 6 month previously , contain gemcitabine platinum salt ) . Previous irradiation ( external radiotherapy , brachytherapy ) PDT allow provide least one unidimensionally measurable target lesion untreated area . 6 . Bilirubin 3 time upper limit normal range ( ULN ) . Pts jaundice evidence bile duct obstruction , biliary tree decompress endoscopic percutaneous endoprothesis subsequent reduction bilirubin Â£ 3 ULN , eligible study . 7 . Aminotransferases ( AST , ALT ) 5 ULN , INR &lt; 1.5 ( follow vitamin K1 injection patient current recent history jaundice bile duct obstruction ) , creatinine 1.5 ULN , neutrophils 1.5 109/L , platelet 100 109/L , hemoglobin 9 g/dL ( red blood cell transfusion need allow ) . 8 . Written informed consent . Note : EGFR tumor status know every pt , neither inclusion/exclusion criterion stratification factor . EGFR expression assess IHC use biopsy surgical material , time prior inclusion study . 1 . Known central nervous system metastasis . 2 . Contraindication history grade 34 allergy reaction one treatment component . 3 . Surgery ( except diagnostic biopsy ) , external radiotherapy , brachytherapy , PDT within 30 day prior start treatment . Prior adjuvant chemotherapy allow complete least 30 day previously ( 6 month contain gemcitabine platinum salt ) . 4 . Participation another clinical trial within 30 day prior start treatment . 5 . Concomitant systemic chronic immunotherapy , chemotherapy , antitumor hormone therapy . 6 . Previous administration EGFR inhibitor EGF . 7 . Active uncontrolled infection , peripheral neuropathy grade 2 , acute subacute bowel obstruction history inflammatory bowel disease , symptomatic coronary disease myocardial infarction past 6 month , congestive heart failure ( NYHA class II ) , interstitial pneumonitis respiratory failure , renal failure . 8 . Pregnancy ( positive bHCG dosage baseline ) , breastfeed , lack effective contraception male female pt reproductive potential . 9 . Other malignancy either currently active last 5 year , except adequately treat situ carcinoma cervix basal squamous cell skin carcinoma . 10 . Legal incapacity physical , psychological mental status interfere pt 's ability terminate study sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>